Published in Cancer Res on September 01, 1995
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science (2010) 6.01
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest (2003) 3.31
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A (2001) 2.96
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J (2007) 2.38
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics (2012) 2.35
Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A (2003) 2.28
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci U S A (1997) 1.95
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol (1996) 1.86
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett (2008) 1.85
A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl (2010) 1.84
Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A (1999) 1.82
Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA. Cancer Discov (2015) 1.82
More effective nanomedicines through particle design. Small (2011) 1.80
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release (2013) 1.77
Imaging angiogenesis and the microenvironment. APMIS (2008) 1.77
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials (2008) 1.70
Biogenic gas nanostructures as ultrasonic molecular reporters. Nat Nanotechnol (2014) 1.70
Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol (1997) 1.64
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A (2009) 1.63
Viruses as anticancer drugs. Trends Pharmacol Sci (2007) 1.63
Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer (2000) 1.60
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release (2011) 1.59
A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proc Natl Acad Sci U S A (2013) 1.55
A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 1.50
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release (2014) 1.46
Applications of chitin and its derivatives in biological medicine. Int J Mol Sci (2010) 1.45
Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics (2013) 1.44
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine (2007) 1.41
Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm (2009) 1.38
Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett (2012) 1.37
Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol (2012) 1.33
Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J (2009) 1.32
Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol (1998) 1.31
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol (2010) 1.30
Liposomes as nanomedical devices. Int J Nanomedicine (2015) 1.29
Challenges in development of nanoparticle-based therapeutics. AAPS J (2012) 1.28
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) (2010) 1.28
Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine (2007) 1.28
Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol (1996) 1.26
Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer (1997) 1.25
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res (2008) 1.24
Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv (2012) 1.22
Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J Am Chem Soc (2012) 1.22
Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res (2010) 1.22
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med (2010) 1.21
Drug delivery to solid tumors by elastin-like polypeptides. Adv Drug Deliv Rev (2010) 1.21
Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. Neoplasia (2000) 1.20
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A (2010) 1.20
Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther (2012) 1.19
Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res (2005) 1.18
Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.17
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm (2008) 1.17
In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc Natl Acad Sci U S A (2010) 1.15
Self-assembly synthesis, tumor cell targeting, and photothermal capabilities of antibody-coated indocyanine green nanocapsules. J Am Chem Soc (2010) 1.13
Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol (2010) 1.12
Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target (2005) 1.12
The Behaviors of Ferro-Magnetic Nano-Particles In and Around Blood Vessels under Applied Magnetic Fields. J Magn Magn Mater (2011) 1.12
Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm (2011) 1.11
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev (2011) 1.11
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One (2009) 1.10
Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano (2010) 1.09
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther (2010) 1.09
Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis (2009) 1.08
Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer (2007) 1.08
A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol (2012) 1.07
Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology (2010) 1.07
Single-cell fluorescence imaging using metal plasmon-coupled probe 2: single-molecule counting on lifetime image. Nano Lett (2008) 1.07
Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia (2005) 1.07
Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine (2008) 1.06
Dynamic visualization of RGD-quantum dot binding to tumor neovasculature and extravasation in multiple living mouse models using intravital microscopy. Small (2010) 1.05
Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05
Nanomaterials for cancer therapy and imaging. Mol Cells (2011) 1.05
Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev (2012) 1.04
Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond) (2010) 1.04
Challenges in development of targeted liposomal therapeutics. AAPS J (2012) 1.03
Indocyanine green-loaded photoacoustic nanodroplets: dual contrast nanoconstructs for enhanced photoacoustic and ultrasound imaging. ACS Nano (2013) 1.03
Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem (2013) 1.03
Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer (2002) 1.03
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Hip morphology influences the pattern of damage to the acetabular cartilage: femoroacetabular impingement as a cause of early osteoarthritis of the hip. J Bone Joint Surg Br (2005) 7.91
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 6.86
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Transport of molecules in the tumor interstitium: a review. Cancer Res (1987) 5.74
In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med (2001) 5.54
Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett (1990) 5.14
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res (2000) 4.89
Femoroacetabular impingement and the cam-effect. A MRI-based quantitative anatomical study of the femoral head-neck offset. J Bone Joint Surg Br (2001) 4.46
Fractals and cancer. Cancer Res (2000) 4.05
Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A (2001) 3.88
Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res (1994) 3.84
Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res (1992) 3.77
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations. Biophys J (1999) 3.26
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol (1998) 3.18
During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med (1996) 3.18
Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res (1990) 3.18
Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A (2000) 3.16
Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res (1992) 3.09
Microvascular permeability of normal and neoplastic tissues. Microvasc Res (1986) 3.04
Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A (2001) 2.96
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res (1989) 2.82
Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol (1997) 2.66
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc Natl Acad Sci U S A (1989) 2.61
Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol (2008) 2.61
Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am J Pathol (1993) 2.60
"SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem (2006) 2.58
Abnormal extension of the femoral head epiphysis as a cause of cam impingement. Clin Orthop Relat Res (2004) 2.50
LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res (2001) 2.48
Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res (1991) 2.45
Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol (1998) 2.41
Fluorescence photobleaching with spatial Fourier analysis: measurement of diffusion in light-scattering media. Biophys J (1993) 2.36
Needle stick injuries among health care workers in a tertiary care hospital of India. Indian J Med Res (2010) 2.32
Hindered diffusion in agarose gels: test of effective medium model. Biophys J (1996) 2.24
Global status of tospovirus epidemics in diverse cropping systems: successes achieved and challenges ahead. Virus Res (2009) 2.14
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res (2001) 2.11
Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res (1999) 2.10
Extravascular diffusion in normal and neoplastic tissues. Cancer Res (1984) 2.04
Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta (1991) 2.01
Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res (1999) 2.00
Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci U S A (1997) 1.95
Predictors of humeral head ischemia after intracapsular fracture of the proximal humerus. J Shoulder Elbow Surg (2004) 1.93
Diffusion and partitioning of proteins in charged agarose gels. Biophys J (1995) 1.92
Increased rates of CD4(+) and CD8(+) T lymphocyte turnover in simian immunodeficiency virus-infected macaques. Proc Natl Acad Sci U S A (1998) 1.88
Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol (1996) 1.86
Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci (1983) 1.85
Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A (1999) 1.82
Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73
Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation (1997) 1.71
Oncotic pressure in solid tumors is elevated. Cancer Res (2000) 1.69
Interstitial hypertension in human breast and colorectal tumors. Cancer Res (1992) 1.67
Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc Res (1993) 1.66
Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther (2008) 1.66
Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res (1995) 1.65
Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol (1997) 1.64
Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am J Physiol (1996) 1.63
Tumor angiogenesis and interstitial hypertension. Cancer Res (1996) 1.63
Secondary tuberculosis of the skin. Clinical features and problems in laboratory diagnosis. Int J Dermatol (1987) 1.62
Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer (2000) 1.60
Role of erythrocytes in leukocyte-endothelial interactions: mathematical model and experimental validation. Biophys J (1996) 1.60
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res (2001) 1.59
Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res (1990) 1.54
Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry. Indian Heart J (2010) 1.50
Demonstration of intramedullary tuberculomas by magnetic resonance imaging: a report of two cases. Br J Radiol (1991) 1.50
Vascular morphogenesis and remodeling in a human tumor xenograft: blood vessel formation and growth after ovariectomy and tumor implantation. Circ Res (2001) 1.50